Thalidomide is a sedative drug discovered at the end of the 50s, it showed high anticancer activity so attempts were made to synthesize thalidomide analogs that had fewer side effects than the parent compound. DPDQA showed higher anticancer activities than thalidomide. Labeling of a DPDQA with 99mTc using Na2S2O4 as reducing agent was performed. The dependence of the radiolabeling yield on the concentrations of DPDQA and reducing agent, pH of the reaction mixture, reaction time, and reaction temperature was studied. Bio-distribution studies in mice with tumor induced in the right thigh were carried out. The tumor infected thigh/contralateral thigh uptake ratio (T/NT) was evaluated. The time for the maximum accumulation of the 99mTc–DPDQA in the tumor site was evaluated after administration of the compound.
El-Zahabi, M. (2021). DESIGN, SYNTHESIS, AND BIOLOGICAL TRACING OF 99MTC- DPDQA AS A POTENTIAL MARKER FOR TUMOR IMAGING. Al-Azhar Journal of Pharmaceutical Sciences, 63(1), 72-85. doi: 10.21608/ajps.2021.153562
MLA
Mohamed El-Zahabi. "DESIGN, SYNTHESIS, AND BIOLOGICAL TRACING OF 99MTC- DPDQA AS A POTENTIAL MARKER FOR TUMOR IMAGING", Al-Azhar Journal of Pharmaceutical Sciences, 63, 1, 2021, 72-85. doi: 10.21608/ajps.2021.153562
HARVARD
El-Zahabi, M. (2021). 'DESIGN, SYNTHESIS, AND BIOLOGICAL TRACING OF 99MTC- DPDQA AS A POTENTIAL MARKER FOR TUMOR IMAGING', Al-Azhar Journal of Pharmaceutical Sciences, 63(1), pp. 72-85. doi: 10.21608/ajps.2021.153562
VANCOUVER
El-Zahabi, M. DESIGN, SYNTHESIS, AND BIOLOGICAL TRACING OF 99MTC- DPDQA AS A POTENTIAL MARKER FOR TUMOR IMAGING. Al-Azhar Journal of Pharmaceutical Sciences, 2021; 63(1): 72-85. doi: 10.21608/ajps.2021.153562
)
View on SCiNiTO